History

  • 2026 ~

    Oct

    · CU01 Phase 2b Results in Diabetic Nephropathy Presented Orally at ICDM 2026

     

    Sep

    · MT-501 selected for an R&D project supported by the Ministry of SMEs and Startups

     

    Aug

    · Selected as a participating company in the Jeonbuk Next-Generation Veterinary Medicines Regulation-Free Special Zone for CP02

    · CU72 selected for the Ministry of SMEs and Startups’ collaborative pharmaceutical–bio venture technology development program

     

    Jun

    · CU01 Phase 2b Results Presented at the ADA 2026

    · MOU with the College of Pharmacy, Gyeongsang National University

    · MOU with AIMBLE, an AI Drug Discovery Company

    · MT-201 Selected for the Korea Drug Development Fund (KDDF) Program

     

    May

    · Preclinical Results of MT-103 Presented Orally at ARVO 2026

    · Retinal Disease Bispecific Antibody MT-103 Licensed to Memento Medicines

     

    Apr

    · CU01 Phase 2b Clinical Trial CSR(Clinical Study Reports) received (Diabetic Nephropathy)

     

    Feb

    · Completed Merger with Active Pharmaceutical Ingredient (API) Company

     

    Jan

    · CU01 Phase 2b Topline Results Announced (Diabetic Nephropathy)

  • 2025

    2025

    Sep
    · Signed an MOU with BORYUNG, to co-develop CU01 


    May
    · CU06 Official International Nonproprietary Name RivasteratRegistered with WHO


    Mar
    · Approvedthe absorptive merger of Daesung Pharmtech, an API company


    Jan
    · CP01 (Chronic Kidney Disease in Companion Animals),Phase 3 IND application approved by the APQA

  • 2024

    2024
    ㅎDec
    · Oral presentation of CU06 diabetic macular edema U.S. phase 2a clinical trial results at ARC 2024 (Asia Retina Congress)

    Oct
    · Signed an MOU with KOREA INSTITUTE OF TOXICOLOGY, for incurable diseases in pets

    Sep
    · e-Poster presentation of CU06 diabetic macular edema U.S. phase 2a clinical trial results at EURETINA 2024

    Jul
    · Co-R&D agreement with MabTics for antibody therapeutics for refractory vascular diseases
    · Oral presentation of CU06 diabetic macular edema U.S. phase 2a clinical trial results at ASRS 2024 (The American Society of Retina Specialists)

    May
    · Poster presentation of CU06 diabetic macular edema U.S. phase 1 clinical trial results at ARVO 2024 (The Association for Research in Vision and Ophthalmology)

    Apr
    · CU06 (Diabetic Macular Edema), U.S. Phase 2a Clinical Trial CSR(Clinical Study Reports) received

    Mar
    · Establishment of Curacle Advanced Institute of Technology (CAIT)

    Feb
    · CU06 (Diabetic Macular Edema), U.S. Phase 2a Clinical Trial Topline Data Announced
  • 2023

    2023

    넣어Dec

    · CU104 (Ulcerative Colitis), Phase 2 IND application approved in Europe


    Sep

    · Co-development agreement with CAND to develop treatments for kidney disease of companion animals


    Jul

    · Signed an MOU with STANDIGM, an artificial intelligence (AI) drug discovery company


    Jun

    · Signed an MOU with MabTics, an antibody therapeutics company
    · CU104 (Ulcerative Colitis), Phase 2 IND application approved by the FDA

    · Signed an MOU with Center for Companion Animal New drug Development (CAND)


    Apr

    · Signed MOU with College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University

  • 2022

    2022

    Dec

    · Acquired high-tech product certification from the Ministry of Trade, Industry and Energy

    · Grand Prize at the 2022 Korea Value Management Award by HANKOOKILBO


    Nov

    · Acquired R&D type venture enterprise certification


    Sep

    · CU06 (Diabetic macular edema), Phase 2a IND application approved

    · New CFO·Vice President Appointed


    Jul

    · CU01 (Diabetic nephropathy), Phase 2b IND application approved


    Jun

    · Computer-Aided drug design
    · CU06, Finalized CU06 Phase1 CSR

    · Posterpresentation of CU01 diabetic nephropathy Phase 2a clinical trial results at2022 American Diabetes Association (ADA) Conference


    Apr

    · Relocated research center and welcomed Seocho Headquarters phase


    Jan

    · Established 2nd bio research center

  • 2021

    호ㅁㅍNov

    · New CEO Appointed


    Oct

    · CU06, Out-licensed to ophthalmology company Thea


    Sep

    · CU01 (Diabetic nephropathy), Submitted Phase 3 IND


    Jul

    · Listed on KOSDAQ (365270)


    May
    · CU06 (Diabetic Macular Edema), Phase 1 IND approved by FDA (NCT04795037)

    · Passed the technical evaluation for Special Technology Assessment Track listing(grade: AA, A)

    · CU01 (Diabetic nephropathy), Confirmed safety and efficacy in Phase 2a clinical trial


    Jan

    · Signed MOU with College of Pharmacy & Institute of Pharmaceutical Science and Technology Research, Korea University

  • 2020

    Dec

    · Signed research agreement with Severance Hospital: Yonsei University Severance Hospital


    Nov

    · CU06 U.S. Clinical DP Production Completed (cGMP)

    · Signed research agreement with Yonsei University and opened industry-academic cooperation biolab

    · Inno-Biz certification (certification number: 200605–01197)


    Sep

    · Introduction and Transition of Electronic Securities System
    · Funding raised (US$ 4 million)


    Aug

    · Awarded ‘Bio-Tech Science Innovation Award’ from “2020 6th Korea Leading Enterprise Awards”

    · CU01 (Diabetic Nephropathy), Completed Test Subject Recruitment for Clinical 2a Phase

    · CU03 (Wet AMD), Completed Clinical 2a Phase tolerability Assessment, Recruited additional 60 subjects

    · Appointment of stock transfer agent (Korea Securities Depository)


    Jun

    · Signed research agreement for formulation development with LS Pharma


    Apr

    · Startups Research Infra Utilization (Research Focused) Grant awarded by the Ministry of SMEs

    · CU06, Pharmaceutical Industry Global Advancement Supporting Grant awarded by the Ministry of Health and Welfare


    May

    · CU06, signed CMO service contract with Yuhan Chemical (South Korea) for cGMP DS production of FDA Phase 1 study


    Jan

    · Established Bio & Analytical Laboratory at Pangyo 2nd Techno Valley



  • 2019

    Dec

    · CU03 (Wet AMD), Phase 2a IND approved by Ministry of Food and Drug Safety (MFDS)


    Nov

    · Signed Consultation contract with BL&H (USA) for global BD
    · Funding raised (US$ 7.1 million)


    Oct

    · Relocated headquarters to Pangyo 2nd Techno Valley
    · CU06, signed CMO service contract with Patheon (USA) for formulation study & cGMP DP production


    Jul

    · Samsung Securities selected as underwriter for IPO


    Jun

    · CU06, Signed CRO service contract with Covance (UK) for global GLP nonclinical study


    May

    · CU01 (Diabetic Nephropathy), Phase 2a IND approved by Ministry of Food and Drug Safety (MFDS)


    Apr

    · CU06, Signed a technology transfer agreement with Yonsei University


    Jan

    · Relocated R&D center (from Daegu Gyeongbuk Medical Innovation Foundation (DGMIF) to Korea Research Institute of  Chemical Technology (KRICT), Daejeon)


  • 2018

    Dec

    · Nominated as a membership business of the Korea Research Institute of Chemical Technology (KRICT)


    Nov

    · Funding raised (US$ 9.0 million)


    Oct

    · Relocated headquarters (Woorim W-city at Pangyo)


    Mar

    · CU05 (Lung Cancer), Grant awarded by the Ministry of Science and ICT for the biomedical technology development business project


    Jan

    · CU02 (NASH & Obesity), Grant awarded by the Ministry of Science and ICT for the biomedical technology development business

  • 2017

    Oct

    · CU04 (immunotherapy), Grant awarded by Daegu-Gyeongbuk

      Medical Innovation Foundation (DGMIF) New Drug Development

      Center for optimization support


    Aug

    · CU02 (NASH & Obesity), Signed Technology transfer agreement

      from Gwangju Institute of Science and Technology (GIST),

      Korea Advanced Institute of Science and Technology (KAIST) &

      Kyungpook National University (KNU)


    Jun

    · CU01, Grant awarded from the Ministry of Trade, Industry and Energy


    May

    · CU01 Signed research contract with Mcnulty for formulation development


    Apr

    · CU05, Signed research agreement with College of Pharmacy, Gachon University


    Mar

    · CU03 (Macular Degeneration), Signed technology transfer

     agreement from Korea Institute of Oriental Medicine (KIOM)


    Feb

    · CU01 (Renal Fibrosis), Signed technology transfer agreement

      from Kyungpook National University
    · CU05 (Lung Cancer), Signed technology transfer agreement

      from Yonsei University


    Jan

    · Established R&D center at Daegu-Gyeongbuk Medical Innovation

      Foundation (DGMIF) certified as affiliated research institute

  • 2016

    2016

    Nov

    · Registered as a venture business (No. 20160300500)

    · Relocated headquarters (Innovalley at Pangyo)


    Oct

    · Funding raised (US$ 1.5 million)


    May

    · Established Curacle Co., Ltd. (Gangnam, Seoul)